Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

<p>Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to enter a potentially registrational Phase 2 clinical study in 2H 2023, with dystrophin data expected in 2024 “R&D Day” virtual […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/wave-life-sciences-reports-second-quarter-2023-financial-results-and-provides-business-update/">Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>